Details

Autor(en) / Beteiligte

• Aldea, Mihaela
• Marinello, Arianna
• Duruisseaux, Michael
• Zrafi, Wael
• Conci, Nicole
• Massa, Giacomo
• Metro, Giulio
• Monnet, Isabelle
• Gomez Iranzo, Patricia
• Tabbo, Fabrizio
• Bria, Emilio
• Guisier, Florian
• Vasseur, Damien
• Lindsay, Colin R.
• Ponce-Aix, Santiago
• Cousin, Sophie
• Citarella, Fabrizio
• Fallet, Vincent
• Minatta, Jose Nicolas
• Eisert, Anna
• de Saint Basile, Hortense
• Audigier-Valette, Clarisse
• Mezquita, Laura
• Calles, Antonio
• Mountzios, Giannis
• Tagliamento, Marco
• Remon Masip, Jordi
• Raimbourg, Judith
• Terrisse, Safae
• Russo, Alessandro
• Cortinovis, Diego
• Rochigneux, Philippe
• Pinato, David James
• Cortellini, Alessio
• Leonce, Camille
• Gazzah, Anas
• Ghigna, Maria-Rosa
• Ferrara, Roberto
• Dall’Olio, Filippo Gustavo
• Passiglia, Francesco
• Ludovini, Vienna
• Barlesi, Fabrice
• Felip, Enriqueta
• Planchard, David
• Besse, Benjamin

Titel

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Ist Teil von

• Journal of thoracic oncology, 2023-05, Vol.18 (5), p.576-586

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Nearly 1% to 2% of NSCLCs harbor RET fusions. Characterization of this rare population is still incomplete. This retrospective multicenter study included patients with any-stage RET positive (RET+) NSCLC from 31 cancer centers. Molecular profiling included DNA/RNA sequencing or fluorescence in situ hybridization analyses. Clinicobiological features and treatment outcomes (per investigator) with surgery, chemotherapy (CT), immune checkpoint blockers (ICBs), CT-ICB, multityrosine kinase inhibitors, and RET inhibitors (RETis) were evaluated. For 218 patients included between February 2012 and April 2022, median age was 63 years, 56% were females, 93% had adenocarcinoma, and 41% were smokers. The most frequent fusion partner was KIF5B (72%). Median tumor mutational burden was 2.5 (range: 1–4) mutations per megabase, and median programmed death-ligand 1 expression was 10% (range: 0%–55%). The most common metastatic sites were the lung (50%), bone (43%), and pleura (40%). Central nervous system metastases were found at diagnosis of advanced NSCLC in 21% of the patients and at last follow-up or death in 31%. Overall response rate and median progression-free survival were 55% and 8.7 months with platinum doublet, 26% and 3.6 months with single-agent CT, 46% and 9.6 months with CT-ICB, 23% and 3.1 months with ICB, 37% and 3 months with multityrosine kinase inhibitor, and 76% and 16.2 months with RETi, respectively. Median overall survival was longer in patients treated with RETi versus no RETi (50.6 mo [37.7–72.1] versus 16.3 mo [12.7–28.8], p < 0.0001). Patients with RET+ NSCLC have mainly thoracic and bone disease and low tumor mutational burden and programmed death-ligand 1 expression. RETi markedly improved survival, whereas ICB may be active in selected patients.